Medication

Clomiphene Citrate

Clomiphene citrate is indicated for the treatment of ovulation dysfunction in women desiring pregnancy. It initiates a series of endocrine events culminating in a rise of follicle stimulating hormone (FSH).

The EMD Serono brand of clomiphene citrate is Serophene® (clomiPHENE citrate tablets USP).

Clomiphene citrate (commonly known as CLOMID®) has been shown to induce ovulation in roughly 80% of women who have trouble ovulating on their own. About half of these women achieve pregnancy during treatment.1

But there’s a flipside to this equation. Roughly 40% to 44% of women treated with clomiphene citrate won't get pregnant.2 That's why it's important to work with your healthcare provider to closely monitor your response to treatment and to discuss other treatment options if clomiphene citrate isn't successful.

How it works

Clomiphene citrate comes in a pill, which a woman will begin taking on the third to the fifth day of her menstrual cycle. The typical starting dose is one 50mg tablet per day for five days. If a cycle is unsuccessful, the healthcare provider may increase the dose by 50mg increments in subsequent cycles.

Clomiphene citrate "tricks" the body into believing that the level of estrogen is low. As a result, the hypothalamus in the brain sends a signal to the pituitary gland to release more FSH and luteinizing hormone (LH) into the bloodstream.

The high level of FSH, in turn, stimulates the development of a follicle and egg. If the treatment cycle is successful, a surge of LH may occur about a week after the last tablet is taken.

This surge of LH causes the egg to be released in a process called ovulation. In some cases, the treatment may result in more than one egg.

If ovulation does occur, fertilizing the released egg, either through timed intercourse or intrauterine insemination, is the next step. Your healthcare provider will determine which method is more likely to lead to successful fertilization.

Your healthcare provider may also choose to use other medications in combination with clomiphene citrate to improve the chances of conception. Low-dose estrogen may be used to thin the cervical mucus, or progesterone may be used to maintain the thickness of the uterine lining (endometrium).

Tracking your response to clomiphene citrate

Monitoring if and when ovulation occurs is a key to successful treatment with clomiphene citrate. During treatment, your healthcare provider will track your response using your menstrual pattern, a basal body temperature (BBT) chart, an ovulation predictor kit, or blood tests to check serum progesterone levels. For a free ovulation kit, just click here and register.

  • Learn more about appropriately timed intercourse
  • Clomiphene citrate therapy comes along with some risks and side effects
  • Always inform your healthcare provider if you experience side effects while taking your medication

If you have questions about taking Serophene® (clomiPHENE citrate tablets USP), please speak to your healthcare provider or call Fertility LifeLines™ at 1-866-LETS-TRY (1-866-538-7879). All calls are free and confidential.

Before you begin treatment with clomiphene citrate, your healthcare provider should first rule out other potential causes of infertility like male tubal factors. These factors will make conception difficult (if not impossible), even if a woman is ovulating.

Once you begin taking clomiphene citrate, you should be aware that the American Society for Reproductive Medicine recommends that patients generally be limited to no more than six ovulatory cycles of this medication.3

At that point, your healthcare provider may recommend pursuing another treatment. And if you're over 35 years of age, you may consider seeing a Fertility Specialist, also called Reproductive Endocrinologist (RE), at an earlier stage.

As with all medications, talk to your healthcare provider about possible risks and side effects if you are prescribed clomiphene citrate.

Important Safety Information
As with all prescription medications, side effects may occasionally occur with use of fertility drugs. Doctors specializing in fertility or reproductive health should only prescribe these products. Patients prescribed gonadotropins and GnRH analogs should be monitored carefully by a trained fertility specialist. Risks include the following events which can be serious: hypersensitivity reactions; ovarian hyperstimulation syndrome (OHSS); pulmonary and vascular complications, and multiple births. For complete product details about a specific fertility drug, please refer to the Full Prescribing Information offered below.

To view the download, you need Adobe® Acrobat® Reader® installed. Don't have Adobe Acrobat Reader on your computer? Download it free, here.

Adobe Acrobat Reader is a registered trademark of Adobe Systems Incorporated.

  • 1. Steiner AZ, Terplan M, Paulson RJ. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum Reprod. 2005;20(6);1511-1515.
  • 2. IBID p-1511,¶2, line 5
  • 3. American Society for Reproductive Medicine. Medications for inducing ovulation: a guide for patients. Birmingham, Alabama: American Society for Reproductive Medicine; 2006.

Get Smarter About Fertility Options.

Check out our resources.

Cool Tools From My Fertility LifeLines™

Try these interactive resources as you embark on your journey.

Personal Stories

Watch videos

Hear from others who have gone through what you and your partner may be experiencing.
Watch videos

FIND A FERTILITY SPECIALIST

Enter your Zip code to find a fertility treatment specialist or fertility clinic in your area:

FIND A UROLOGIST

The Society for the Study of Male Reproduction (SSMR) can help you locate a urologist in your area.

Locate a Urologist

Important Safety Information:
Gonal-f® RFF Pen (follitropin alfa injection) is indicated for the induction of ovulation and pregnancy in the oligo-anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure. Gonal-f® RFF Pen is also indicated for the development of multiple follicles in the ovulatory patient participating in an Assisted Reproductive Technology (ART) program. Gonal-f® RFF Pen (follitropin alfa injection) should only be prescribed by physicians specializing in fertility or reproductive health. Gonal-f® is a potent gonadotropic substance capable of causing mild to severe adverse reactions, including Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary or vascular complications, and multiple births. Gonal-f® is contraindicated in women who exhibit prior hypersensitivity to FSH preparations, primary gonadal failure, uncontrolled thyroid or adrenal dysfunction and pregnancy. Nursing women should not use Gonal-f®. Common side effects include headache, abdominal pain, enlarged abdomen, and injection site disorders. For complete product details, see full prescribing information.

Important Safety Information:
Women: Gonal-f® (follitropin alfa for injection) is indicated for the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure. Gonal-f® is also indicated for the development of multiple follicles in the ovulatory patient participating in an Assisted Reproductive Technology (ART) program.
Men: Gonal-f® (follitropin alfa for injection) is indicated for the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure. Gonal-f® (follitropin alfa for injection) should only be prescribed by physicians who are thoroughly familiar with infertility problems and their management. Gonal-f® is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary or vascular complications. Gonal-f® is contraindicated in women and men who exhibit prior hypersensitivity to recombinant FSH preparations or one of their excipients, high levels of FSH indicating primary gonadal failure, uncontrolled thyroid or adrenal dysfunction, sex hormone dependent tumors of the reproductive tract and accessory organs, and an organic intracranial lesion such as a pituitary tumor; and in women who exhibit abnormal uterine bleeding of undetermined origin, ovarian cyst or enlargement of undetermined origin and pregnancy. Women who are pregnant or nursing should not use Gonal-f®. The most common side effects in patients using Gonal-f® include headache, ovarian cysts, nausea and upper respiratory infections in women and in men, acne, breast pain and growth, and fatigue. Injection site reactions were also reported. Reports of multiple births have been associated with Gonal-f® treatment. For complete product details, see the full prescribing information.

For complete product details, please read the Prescribing Information offered below.


© EMD Serono, Inc. CIM Last Update 2008-09-16
This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

This site contains information that is intended for US residents only. Canadian residents should consult the EMD Serono Canada Inc. Web site at www.emdserono.ca for information on products and services approved in Canada.

EMD Serono

Close

Please wait... loading